Radioligand Therapy Market Research: Key Drivers and Industry Developments
Author : ashlesha more | Published On : 30 Oct 2026
The global radioligand therapy market was valued at USD 3.32 billion in 2025 and is projected to reach USD 31.76 billion by 2034, registering a compound annual growth rate (CAGR) of 28.52% from 2026 to 2034. Demand for targeted cancer treatments, advances in radiopharmaceutical development, and investment in specialized manufacturing infrastructure are shaping the industry's outlook. North America held the largest regional share in 2025, while Europe is expected to record the fastest regional expansion.
Radioligand Therapy Market Key Takeaways
- Market Size (2025): USD 3.32 billion
- Market Size (2026): USD 4.27 billion
- CAGR (Forecast Period): 28.52%
- Forecast Year: 2034
- Projected Market Size (2034): USD 31.76 billion
- Dominant Region: North America
- Fastest-Growing Region: Europe
Market Overview
Radioligand therapy combines a targeting molecule with a radioactive isotope to deliver radiation to specific cancer cells. This approach enables clinicians to direct treatment toward tumors expressing particular molecular targets while limiting exposure to surrounding healthy tissues.
The market includes radiopharmaceuticals, isotope production, specialized manufacturing, and clinical administration services. Lutetium-177-based treatments have an established role in prostate cancer and neuroendocrine tumor care, while research into additional isotopes and molecular targets is broadening the treatment pipeline.
Radioligand Therapy Market Growth Drivers
The need for treatment options for advanced cancers is encouraging the adoption of targeted radiopharmaceuticals. Molecular imaging, including prostate-specific membrane antigen (PSMA) PET scans, helps clinicians identify eligible patients and plan appropriate treatment.
Investment in specialized production facilities also strengthens supply capabilities. In November 2025, Novartis opened a 10,000-square-foot radioligand therapy manufacturing facility in Carlsbad, California, expanding its U.S. manufacturing network.
Radioligand Therapy Market Challenges
Radioligand therapies require specialized manufacturing, radioactive material handling, and time-sensitive distribution. These requirements can increase operational complexity and limit supply where production facilities and trained personnel are insufficient.
Access to nuclear medicine departments, suitable treatment infrastructure, and molecular imaging services also varies across healthcare systems. These differences can affect treatment availability and the pace of adoption.
Radioligand Therapy Market Opportunities
Research into new molecular targets, including fibroblast activation protein and gastrin-releasing peptide receptors, creates opportunities to develop treatments for additional cancer types. Actinium-225 also attracts research interest because of its potential in targeted alpha therapy.
Investment in radiopharmaceutical manufacturing and partnerships with specialized cancer centers can help developers strengthen production capacity, clinical research, and treatment distribution.
Radioligand Therapy Market Segment Analysis
Lutetium-177 held the largest isotope-category share at 58.7% in 2025, reflecting its established use in targeted cancer treatments. Actinium-225 is projected to register the highest isotope-segment CAGR of 20.4%.
The prostate-specific membrane antigen segment accounted for 67.5% of the target category in 2025. By indication, prostate cancer is projected to register a CAGR of 17.4%, while cancer treatment centers are expected to record the highest end-user CAGR of 17.2%.
Radioligand Therapy Market Regional Analysis
North America dominated the market with a 42.6% share in 2025. Established nuclear medicine facilities, clinical research networks, and specialized cancer treatment services contribute to regional adoption.
Europe is projected to register a CAGR of 17.3%, making it the fastest-growing region. Asia Pacific is expected to record a CAGR of 16.4%, supported by expanding oncology infrastructure and efforts to strengthen radiopharmaceutical capabilities.
Radioligand Therapy Market Competitive Landscape
The market includes pharmaceutical companies, radiopharmaceutical manufacturers, isotope producers, and biotechnology developers. Key companies include:
- Novartis AG
- Bayer AG
- Curium Pharma
- Lantheus Holdings, Inc.
- Telix Pharmaceuticals
Competition centers on product development, regulatory approvals, clinical evidence, isotope access, manufacturing capacity, and distribution partnerships.
Click Here to Access the Comprehensive Report:https://straitsresearch.com/report/radioligand-therapy-market
Radioligand Therapy Market Future Outlook
The radioligand therapy market is expected to benefit from advances in targeted treatments, expanded manufacturing networks, and research into additional molecular targets. Wider access will depend on reliable isotope supplies, specialized treatment facilities, and clinical expertise. Companies investing in production capabilities and innovative radiopharmaceutical pipelines may be better positioned to address evolving oncology needs.
About Straits Research
Straits Research is a global market intelligence and consulting company that provides market research, industry analysis, forecasts, and strategic insights across multiple sectors. The company helps businesses evaluate market dynamics, understand competitive environments, and identify commercial opportunities.
